Policlinica Gipuzkoa S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Neurology department at Policlinica Gipuzkoa S.A. is also conducting important cardiovascular research, focusing on conditions such as Acute myocardial infarction and Spontaneous Coronary Artery Dissection. Trials aim to assess the effectiveness of established medical therapy, including beta‑blockers and antiplatelet agents, as well as novel treatments like a fast‑acting anti‑platelet drug, with the goal of improving outcomes after heart events.
- Acute myocardial infarction
- Spontaneous Coronary Artery Dissection
- Evaluation of beta‑blocker and antiplatelet therapy
- Assessment of novel anti‑platelet agent selatogrel
- Cardiovascular safety and tolerability monitoring
With 20 active clinical trials and a team of 15 investigators, the site provides a collaborative environment for advancing cardiovascular care in Europe, while maintaining a patient‑focused approach.
Nervous System Diseases
In the field of Nervous System Diseases, Policlinica Gipuzkoa S.A. is exploring innovative therapies for neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Studies evaluate disease‑modifying antibodies, oral small‑molecule agents, and long‑term safety of investigational products, seeking to slow cognitive decline and motor progression in early‑stage patients.
- Early Alzheimer’s disease
- Early Parkinson’s disease
- Mild cognitive impairment
- Disease‑modifying antibodies
- Neuroprotective oral agents
The neurology team’s multidisciplinary expertise supports comprehensive assessments, aiming to improve both functional outcomes and quality of life for individuals living with progressive neurological conditions.
Mental Disorders
Research on Mental Disorders at the site addresses cognitive and psychiatric aspects of neurodegenerative disease, as well as broader mental health challenges. Clinical investigations test novel compounds intended to enhance cognition, reduce neuropsychiatric symptoms, and support overall mental well‑being, with an emphasis on safety, tolerability, and real‑world effectiveness.
- Cognitive decline in Alzheimer’s disease
- Neuropsychiatric symptom management
- Evaluation of emerging psychotropic agents
- Quality‑of‑life and functional outcomes
- Integrated diagnostic approaches
By integrating neurology and psychiatry expertise, Policlinica Gipuzkoa S.A. contributes to advancing therapeutic options that aim to improve mental health and daily functioning for patients across the disease spectrum.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 4 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG6trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Policlinica Gipuzkoa S.A.
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetaben (18F) | 3 | Unknown | 2024-03-29 | 2025-11-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.